摘要
目的:探讨肥胖相关基因与利培酮治疗所致体质量增加的关联。方法:收集符合美国精神障碍诊断与统计手册第4版(DSM-Ⅳ)诊断的236名汉族精神分裂症患者,所有患者均采用利培酮单一药物治疗,分别于治疗前和治疗4周后测量患者体质量与身高,计算体质量指数(BMI);本研究采用DNA测序检测方法对肥胖相关基因上的rs9939609多态性位点进行基因分型,采用stepwise线性多元回归的方法探索肥胖相关基因rs9939609多态性与利培酮治疗4周所致体质量增加的关联。结果:关联分析结果显示肥胖相关基因rs9939609多态性与基线BMI值无显著关联[AA/AT vs.TT=(23.0±3.6)vs.(22.7±3.5),P=0.245];4周末时,AA/AT基因型携带者与TT基因型携带者BM I值也无显著性差异[AA/AT vs.TT=(23.4±3.6)vs.(22.7±3.5),P=0.090];4周BM I变化值与rs9939609显著关联[AA/AT vs.TT=(0.6±1.1)vs.(0.2±1.3),P=0.040]。结论:本研究结果提示在中国汉族样本人群中,肥胖相关基因rs9939609多态性可能与利培酮所致体质量增加有关联。
Objectives： To explore the association between the Fat Mass and Obesity Associated （FTO） gene polymorphism and weight gain associated with risperidone treatment. Methods： Totally 236 schizophrenic patients met the Diagnostic mad Statistical Manual of Mental Disorders, Fourth Edition （DSM-IV） criteria were enrolled in our study. All the patients were treated with risperidone. The body weight and height of the patients were measured before and after 4week risperidone treatment to calculate body mass index. The FTO rs9939609 polymorphism was genotyped by using direct DNA sequencing method, and was analyzed for association with risperidone-induced weight gain. Results： There was no significant association between rs9939609 and baseline BMI[ AA/AT vs. TT = （23.0 ±3.6） vs. （22.7 ±3.5）, P 〉0. 05] and rs993961Y） was neither associated with 4-week BMI [ AA/AT vs. TT = （23.4 ±3.6） vs. （ 22.7 ± 3. 5）, P 〉 0. 05 ]. There was a significant association between rs9939609 of FTO and BMI change, TT-carriers experienced higher BMI gain than AA/AT-carriers [（0. 6± 1.1） vs. （0. 2 ± 1.3）, P 〈 0.05]. Conclusion： It suggests that FTO gene polymorphism may be associated with weight gain associatied with risperidone treatment in this Chinese Han population.
出处
《中国心理卫生杂志》
CSSCI
CSCD
北大核心
2013年第2期157-160,共4页
Chinese Mental Health Journal
基金
国家自然科学基金(85071087)
863专题项目(2009AA022702,2008AA02Z401)
北京市科技新星计划(2009A03)
